eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For 50 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
Biotics Research is proud to expand our commitment to education with the Wellness Unfiltered Pro Podcast. Each episode delves into key health topics and the clinical applications of our premier products. Through candid, insightful conversations, our team offers practical guidance to keep you informed and empowered as a healthcare professional.
November 19 2026
The journal European Child & Adolescent Psychiatry recently published the results of a systematic review and dose-response meta-analysis evaluatin...

The journal European Child & Adolescent Psychiatry recently published the results of a systematic review and dose-response meta-analysis evaluating the relationship between maternal 25-hydroxyvitamin D (25(OH)D) levels during pregnancy and the risk of diagnosis and symptoms of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children. This analysis included a total of 15 studies with a mix of case-control and cohort studies investigating either a diagnosis or symptoms of ADHD or ASD. Analysis of the 8 studies investigating ASD found a “consistent evidence of a protective association of vitamin D,” with an overall 9% significant reduction in ASD diagnosis. This appeared to be a dose-dependent linear relationship; for every 10 nmol/L increase in maternal 25(OH)D there was a 9% lower risk. For example, for mothers with the highest 25(OH)D of 90 nmol/L, there was approximately a 50% lower incidence of ASD diagnosis. There was also a small but significant reduction in ASD symptoms with higher 25(OH)D levels. Similar results were found for ADHD, with an approximately a 10% overall significant reduction in risk for a diagnosis, and a small but non-significant reduction in symptoms.
A number of plausible mechanisms of action are suggested by the authors, primarily related to a beneficial role of vitamin D in fetal brain development, including modulation of neurotransmitter synthesis and regulation of immune/inflammatory pathways, as well as neuron growth and development. For example, a number of preclinical studies suggest that maternal immune activation, marked by oxidative stress, mitochondrial dysfunction, neuroinflammation (with an upregulation of inflammatory cytokines), etc., may be contributing factors. In one experimental mouse study, vitamin D supplementation during pregnancy helped to alleviate this immune activation, inhibiting inflammatory cytokine production and improving ASD-like behavior in offspring.
There is some evidence in humans that 25(OH)D during pregnancy may be more important than during early childhood, at least in terms of ASD risk. For example, in one double-blind, randomized controlled trial known as the vitamin D intervention in infants (VIDI), nearly 400 Finnish children aged 6 to 8 were given either 400 IU or 1200 IU vitamin D3 when they were between 2 weeks and 2 years old. There was no significant benefit of the higher dose (and no placebo to compare with), though 25(OH)D levels among boys (not girls) were inversely associated with scores on the Autism Spectrum Screening Questionnaire (ASSQ). Thus, it’s not clear that supplementation during early childhood lowers risk, though risk was still linked to 25(OH)D during infancy, at least in boys.
In one older study with no placebo and an open-label design (thus inherently limited in its conclusions), women who had previously had a child with ASD were supplemented with vitamin D during pregnancy (5,000 IU per day), with their children supplemented at 1,000 IU per day until reaching age 3 (nursing mothers were also supplemented at 7,000 IU per day). Although a small study, they report only 1 child developing ASD (5%) compared to a literature prevalence of 20%. More studies evaluating multiple doses, potentially influenced by BMI and other factors, given at various time points (before conception, during pregnancy, etc.) may help to establish potential benefit, and if there is an optimal window for supplementation.
Submit this form and you'll receive our latest news and updates.
The results of the Vitamin D and omega 3 trial (VITAL), originally published in BMJ in 2022, found that vitamin D supple...
Learn moreAn abstract presented at the American Heart Association’s 2025 Scientific Sessions suggests that personalized supplement...
Learn moreThe American Journal of Clinical Nutrition recently published the results of a randomized and placebo-controlled trial e...
Learn more
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Biotics Research Corporation - All Rights Reserved
Submit your comment